AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3553247
Drug: Clobetasol‐17‐propionate ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobetasol‐17‐propionate ointment
Trial: 3553247
Drug: Both drugs
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drugs (Betamethasone and Clobetasol)
Trial: 24612495
Drug: Various interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Various interventions to improve adherence (e.g., calendar blister packs, patient education programs)
Trial: 24612495
Drug: Simplification of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simplification of drug regimens (e.g., reducing the number of pills taken per day)
Trial: 23724808
Drug: Adapalene 0.1%
RxNorm normalized name: ADAPALENE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapalene 0.1% gel plus nadifloxacin 1% cream (combination therapy)
Trial: 23724808
Drug: Adapalene 0.1%
RxNorm normalized name: ADAPALENE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapalene 0.1% gel (monotherapy)
Trial: 20010312
Drug: Enzyme-linked immunosorbent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme-linked immunosorbent assay cutoff of 0.2 microg/mL
Trial: 18829518
Drug: Ibandronate 150
RxNorm normalized name: ibandronate 150 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate 150 mg orally every month
Trial: 19382218
Drug: Fluticasone propionate/salmeterol
RxNorm normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate/salmeterol (100/50 mcg twice daily)
Trial: 19382218
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (100 mcg twice daily)
Trial: 15688622
Drug: Pegylated liposomal
RxNorm normalized name: doxorubicin HCl pegylated liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated liposomal doxorubicin (PLD) 50 mg/m2 day 1 every 4 weeks
Trial: 15688622
Drug: Topotecan 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan 1.5 mg/m2 daily for 5 days q 21
Trial: 11301569
Drug: Ketoprofen 6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 6.25 mg
Trial: 27027878
Drug: Insulin degludec/insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin degludec/insulin aspart (IDegAsp) once daily
Trial: 21134466
Drug: Inactivated Ph.d.p.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated Ph.d.p. whole bacterial vaccine
Trial: 19552838
Drug: Serum Chemerin
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum Chemerin levels in females (109 +/- 28 microg/L)
Trial: 19552838
Drug: Serum Chemerin
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum Chemerin levels in OW/OB group (113 +/- 27 microg/L)
Trial: 17094871
Drug: Oral melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral melatonin 3 mg (M3 group)
Trial: 17094871
Drug: Oral melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral melatonin 5 mg (M5 group)
Trial: 14743850
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (both groups)
Trial: 9476036
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg zolmitriptan alone
Trial: 9476036
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg zolmitriptan + 1 g paracetamol
Trial: 9476036
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg zolmitriptan + 10 mg metoclopramide
Trial: 9476036
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg zolmitriptan + 1 g paracetamol + 10 mg metoclopramide
Trial: 3129954
Drug: Pethidine 30
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pethidine 30 mg and doxapram 45 mg
Trial: 3129954
Drug: Pethidine 30
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pethidine 30 mg alone
Trial: 20850831
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment group (electrical stimulation)
Trial: 11952661
Drug: Topical mupirocin
RxNorm normalized name: mupirocin Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical mupirocin cream applied three times daily
Trial: 11952661
Drug: Oral cephalexin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cephalexin, 250 mg four times daily
Trial: 10217339
Drug: Caffeine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (100 mg four times daily)
Trial: 10217339
Drug: Mexiletine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexiletine (200 mg oral dose)
Trial: 7899419
Drug: piperacillin (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: piperacillin (12 g/d)/tazobactam (1.5 g/d)+amikacin
Trial: 7899419
Drug: ceftazidime (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ceftazidime (3 g/d)+amikacin
Trial: 822265
Drug: niflumic acid
RxNorm normalized name: niflumic acid
DrugBank: Niflumic acid (DB04552)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: niflumic acid (1000 mg per day)
Trial: 822265
Drug: indometazin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: indometazin (100 mg per day)
Trial: 24426779
Drug: menatetrenone 45
RxNorm normalized name: Menatetrenone 45 MCG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: menatetrenone 45 mg/day
Trial: 24426779
Drug: alfacalcidol 0.5
RxNorm normalized name: alfacalcidol 0.5 MCG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alfacalcidol 0.5 μg/day
Trial: 15857725
Drug: Weekly individual
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly individual standardized interpersonal cognitive psychotherapy
Trial: 15857725
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg buprenorphine every other day
Trial: 14694974
Drug: Porcine-derived lung
RxNorm normalized name: porcine lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Porcine-derived lung surfactant therapy within the first hour of life (Group A, 35 neonates)
Trial: 14694974
Drug: No surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No surfactant therapy within the first hour of life (Group B, 40 neonates)
Trial: 14694974
Drug: Porcine-derived lung
RxNorm normalized name: porcine lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Porcine-derived lung surfactant therapy within the first hour of life (Group A)
Trial: 14694974
Drug: No surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No surfactant therapy within the first hour of life (Group B)
Trial: 2938515
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide as inhalation powder (40 micrograms)
Trial: 31662373
Drug: Internet-Based Exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-Based Exercise programme (iBEAT-OA), 20-30 min daily for six weeks
Trial: 30353809
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg regular‐release melatonin
Trial: 22067793
Drug: LNG/EE (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNG/EE (90 mcg levonorgestrel/20 mcg ethinyl estradiol)
Trial: 18798585
Drug: Topical 0.02%
RxNorm normalized name: tretinoin topical 0.02% topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.02% mitomycin-C drops twice a day for 2 weeks after pterygium excision
Trial: 15851601
Drug: Clopidogrel and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel and Aspirin (dual therapy)
Trial: 15851601
Drug: Aspirin monotherapy
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin monotherapy (control)
Trial: 11403068
Drug: Heparin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (250 IU/h, adjusted in 125 IU/h steps, targeted ACT 180-210 s)
Trial: 9663728
Drug: effervescent cimetidine
RxNorm normalized name: cimetidine Effervescent Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: effervescent cimetidine 200 mg
Trial: 7833101
Drug: Fadrozole hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Fadrozole (DB16832)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fadrozole hydrochloride 0.5 mg bd
Trial: 7833101
Drug: Fadrozole hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Fadrozole (DB16832)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fadrozole hydrochloride 1.0 mg bd
Trial: 7833101
Drug: Fadrozole hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Fadrozole (DB16832)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fadrozole hydrochloride 2.0 mg bd
Trial: 3275684
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg cabergoline
Trial: 3275684
Drug: 0.6 mg
RxNorm normalized name: thymol 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg cabergoline
Trial: 3275684
Drug: 0.6 mg
RxNorm normalized name: thymol 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg cabergoline (twice weekly)
Trial: 1489388
Drug: Iodine-131 therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodine-131 therapy
Trial: 31291863
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (group 2)
Trial: 1489388
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (group 2)
Trial: 860807
Drug: Oral diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diazepam and metoclopramide with a drink
Trial: 26375928
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (30 IU)
Trial: 23147384
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg day(‐1) GSK1521498
Trial: 23147384
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg day(‐1) GSK1521498
Trial: 3336100
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine viscous solution
Trial: 29282731
Drug: TAU plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAU plus up to 16 sessions of individual formulation‐based CBT for ADHD
Trial: 23615694
Drug: Aripiprazole once-monthly
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole once-monthly (ARI-OM)
Trial: 19491792
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment during hospitalization
Trial: 19491792
Drug: Conservative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative therapy following stapedoplasty (1 year or more earlier)
Trial: 19491792
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with betahistine dihydrochloride (betaserk) during 2 months and 10-12 sessions of game exercises at a stabilographic complex
Trial: 17110823
Drug: Nontricyclic antidepressant
RxNorm normalized name: TRICYCLIC ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nontricyclic antidepressant
Trial: 9934406
Drug: Cetirizine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (10 mg/die per os) + Placebo of fluticasone (2 puff per nostril once daily by aerosol) for 60 days
Trial: 9934406
Drug: Fluticasone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone (100 mg per nostril once daily by aerosol) + Placebo of cetirizine (per os) for 60 days
Trial: 9934406
Drug: Cetirizine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (10 mg/die per os) + Fluticasone (100 mg per nostril once daily by aerosol) for 20 days
Trial: 9934406
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Cetirizine and Fluticasone)
Trial: 8148218
Drug: Colestipol 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colestipol 10 g daily (administered as 5 g twice daily or 10 g once daily)
Trial: 3246466
Drug: Carbohydrate (CHO)
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate (CHO) solution
Trial: 3246466
Drug: Placebo (PL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PL) solution
Trial: 31305338
Drug: Methadone 5
RxNorm normalized name: methadone 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone 5 mg
Trial: 31305338
Drug: Buprenorphine 0.4
RxNorm normalized name: buprenorphine 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 0.4 mg
Trial: 16738349
Drug: Cognitive Stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Stimulation Therapy (CST) group intervention, twice weekly for 8 weeks
Trial: 9102064
Drug: Etidronate 400
RxNorm normalized name: etidronate 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etidronate 400 mg once daily for 14 days followed by 76 days of 500 mg of elementary calcium once daily, repeated every 3 months.
Trial: 9102064
Drug: Calcium 500
RxNorm normalized name: Calcium 500+D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium 500 mg once daily.
Trial: 3896368
Drug: Short peri-operative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short peri-operative antibiotic course
Trial: 3896368
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no antibiotic course)
Trial: 31819863
Drug: Silicone gel
RxNorm normalized name: SILTREX Silicone Gel-Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone gel treatment applied twice per day for two months on the surgical wound site.
Trial: 31819863
Drug: Placebo (Vaseline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Vaseline) treatment applied twice per day for two months on the surgical wound site.
Trial: 15889513
Drug: Medication (Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (Control group I)
Trial: 9501783
Drug: intra‐umbilical vein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intra‐umbilical vein injection of saline solution plus oxytocin
Trial: 9501783
Drug: intra‐umbilical vein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intra‐umbilical vein injection of saline solution alone
Trial: 7698575
Drug: Sulindac (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulindac (150 mg twice daily for 4 months)
Trial: 1671875
Drug: 2-chlorodeoxyadenosine (2-CDA)
RxNorm normalized name: 2-Chlorodeoxyadenosine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2-chlorodeoxyadenosine (2-CDA) at doses of 3 to 10.7 mg/m2/d, given as a continuous 5-day infusion
Trial: 31699716
Drug: Tablet-based application
RxNorm normalized name: BAKING POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based application used by community health agents (CHAs) during home visits to improve child-rearing practices and child health indicators.
Trial: 31699716
Drug: Tablet-based application
RxNorm normalized name: BAKING POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based application used by CHAs.
Trial: 28151802
Drug: Erythropoietin (40,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (40,000 IU) - 1 dose
Trial: 28151802
Drug: Erythropoietin (40,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (40,000 IU) - 2 doses
Trial: 28151802
Drug: Erythropoietin (40,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (40,000 IU) - 3 doses
Trial: 28151802
Drug: Placebo (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (no doses of erythropoietin)
Trial: 23030579
Drug: Pharmacist intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist intervention including medication reconciliation, inpatient counseling, simple adherence aids, and telephone follow‐up
Trial: 20520621
Drug: Saffron (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saffron (30 mg twice daily for 12 weeks)
Trial: 10190759
Drug: Sertraline tablet
RxNorm normalized name: sertraline Oral Tablet
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline tablet formulation made in China (test tablet)
Trial: 10190759
Drug: Sertraline tablet
RxNorm normalized name: sertraline Oral Tablet
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline tablet formulation made in England (reference tablet)
Trial: 8027273
Drug: Ovulation induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovulation induction using a luteinizing hormone-releasing hormone agonist plus human menopausal gonadotrophin
Trial: 2574729
Drug: Dilevalol 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilevalol 100 mg bid for 2 weeks
Trial: 2574729
Drug: Dilevalol 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilevalol 200 mg bid for 2 weeks
Trial: 2574729
Drug: Dilevalol 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilevalol 400 mg bid for 2 weeks
Trial: 2574729
Drug: Dilevalol once-a-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilevalol once-a-day dosing (same total daily dose as prior 2 weeks)
Trial: 1937998
Drug: Dilevalol (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilevalol (all doses)
Trial: 7342
Drug: beta‐adrenoceptor antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta‐adrenoceptor antagonists
Trial: 31621256
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received mosapride citrate (5 mg, 3 times a day), bifidobacterium triple viable capsules (420 mg, twice a day), omeprazole (40 mg, twice a day), and antibiotics.
Trial: 23817699
Drug: salsalate, 3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salsalate, 3.5 g/d
Trial: 18294741
Drug: MF59™-adjuvanted vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59™-adjuvanted vaccine
Trial: 16754711
Drug: Prasugrel (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (40 mg loading, 7.5 mg maintenance, n = 1)
Trial: 16754711
Drug: Prasugrel (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (60 mg loading, 10 mg maintenance, n = 4)
Trial: 16754711
Drug: Prasugrel (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (60 mg loading, 15 mg maintenance, n = 2)
Trial: 16754711
Drug: Clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300 mg loading, 75 mg maintenance, n = 2)
Trial: 16754711
Drug: Prasugrel (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (10 mg daily, n = 2)
Trial: 12789875
Drug: Fall-focused pharmaceutical
RxNorm normalized name: PHARMACEUTICAL GLAZE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fall-focused pharmaceutical intervention program (FFPIP)
Trial: 10641431
Drug: Hypnotic suggestions
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic suggestions (difficulty level not specified)
Trial: 22732098
Drug: Individually prescribed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individually prescribed cognitive behavior therapy text modules with online therapist guidance
Trial: 18596312
Drug: Erythromycin 250
RxNorm normalized name: erythromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 250 mg IV every 6 hours
Trial: 18596312
Drug: Metoclopramide 10
RxNorm normalized name: metoclopramide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 10 mg IV every 6 hours
Trial: 8523926
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of desmopressin acetate (DDAVP) at a dosage of 0.3 micrograms/kg, 35 minutes prior to plasmapheresis.
Trial: 1838424
Drug: ICI 192,605
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 192,605 (100 mg orally)
Trial: 6957991
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Pirenzepine daily
Trial: 6957991
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg Cimetidine daily
Trial: 24852584
Drug: Oral bottled
RxNorm normalized name: danicopan
DrugBank: Danicopan (DB15401)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bottled water
Trial: 24852584
Drug: Intravenous normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous normal saline (maximum 2 L over 2 hours)
Trial: 21342170
Drug: 1% nadifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% nadifloxacin cream
Trial: 17097761
Drug: Caralluma extract
RxNorm normalized name: CARALLUMA FIMBRIATA EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caralluma extract (1 g per day for 60 days)
Trial: 8022537
Drug: Gabapentin as
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin as add-on therapy